{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:20:02Z","timestamp":1779200402793,"version":"3.51.4"},"reference-count":35,"publisher":"Walter de Gruyter GmbH","issue":"12","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2024-0351_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the long-term effectiveness of weekly vs. daily growth hormone (GH) administration in children with GH deficiency.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0351_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study, part of the \u201cLG Growth Study\u201d, included a total of 996 children with GH deficiency (773 receiving daily GH and 193 receiving weekly GH). Anthropometric data were collected at baseline and every 12\u00a0months; clinical and laboratory data were collected at baseline and throughout the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0351_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline, the weekly GH group was older, shorter in mid-parental height (MPH), and had more pubertal boys compared to the daily GH group (age: 8.46\u00a0\u00b1\u00a03.44 vs. 7.46\u00a0\u00b1\u00a02.89 years, p&lt;0.001; MPH:\u00a0\u22120.88\u00a0\u00b1\u00a00.73 SD vs.\u00a0\u22121.02\u00a0\u00b1\u00a00.84 SD, p=0.044; pubertal boys: 34.0 vs. 16.9\u202f%, p=0.006). Height velocity and change in height SDS during the first 12\u00a0months were higher in the daily GH group (height velocity: 9.06\u00a0\u00b1\u00a01.72 vs. 8.67\u00a0\u00b1\u00a01.98\u202fcm\/year, p=0.028; height SDS change: 0.78\u00a0\u00b1\u00a00.39 vs. 0.61\u00a0\u00b1\u00a00.41, p&lt;0.001). However, height SDS at 24 and 48\u00a0months were similar between groups. No significant differences in overall height velocity, annualized treatment continuation rate, and safety profile were observed over 48\u00a0months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0351_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Weekly GH therapy appears to be an effective and safe alternative to daily GH treatment in children with GH deficiency over a 4-year period. Further research with larger sample sizes and longer follow-up is needed to confirm these findings and assess the extended safety and effectiveness of LAGH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2024-0351","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T13:21:54Z","timestamp":1729171314000},"page":"1036-1046","source":"Crossref","is-referenced-by-count":3,"title":["Long-term effectiveness and safety of long-acting growth hormone preparation in children with growth hormone deficiency"],"prefix":"10.1515","volume":"37","author":[{"given":"Eungu","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Pediatrics , Korea University College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey Yoojin","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Korea University College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Jun","family":"Rhie","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Korea University College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kee-Hyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Korea University College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1512-2062","authenticated-orcid":false,"given":"Hyo-Kyoung","family":"Nam","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Korea University College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"2024120211230932585_j_jpem-2024-0351_ref_001","doi-asserted-by":"crossref","unstructured":"Richmond, E, Rogol, AD. Treatment of growth hormone deficiency in children, adolescents and at the transitional age. Best Pract Res Clin Endocrinol Metabol 2016;30:749\u201355. https:\/\/doi.org\/10.1016\/j.beem.2016.11.005.","DOI":"10.1016\/j.beem.2016.11.005"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_002","doi-asserted-by":"crossref","unstructured":"Yoon, JY, Cheon, CK, Lee, JH, Kwak, MJ, Kim, HJ, Kim, YJ, et al.. Response to growth hormone according to provocation test results in idiopathic short stature and idiopathic growth hormone deficiency. Ann Pediatr Endocrinol Metab 2022;27:37\u201343. https:\/\/doi.org\/10.6065\/apem.2142110.055.","DOI":"10.6065\/apem.2142110.055"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_003","doi-asserted-by":"crossref","unstructured":"Lee, HS. The effects of growth hormone treatment on height in short children. Ann Pediatr Endocrinol Metab 2022;27:1\u20132. https:\/\/doi.org\/10.6065\/apem.2221055edi01.","DOI":"10.6065\/apem.2221055edi01"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_004","doi-asserted-by":"crossref","unstructured":"Geffner, ME, Ranke, MB, Wajnrajch, MP. An overview of growth hormone therapy in pediatric cases documented in the kabi international growth study (pfizer international growth database). Ann Pediatr Endocrinol Metab 2024;29:3\u201311. https:\/\/doi.org\/10.6065\/apem.2346206.103.","DOI":"10.6065\/apem.2346206.103"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_005","doi-asserted-by":"crossref","unstructured":"Allen, DB, Backeljauw, P, Bidlingmaier, M, Biller, BM, Boguszewski, M, Burman, P, et al.. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol 2016;174:P1\u20139. https:\/\/doi.org\/10.1530\/eje-15-0873.","DOI":"10.1530\/EJE-15-0873"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_006","doi-asserted-by":"crossref","unstructured":"Grimberg, A, DiVall, SA, Polychronakos, C, Allen, DB, Cohen, LE, Quintos, JB, et al.. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr 2016;86:361\u201397. https:\/\/doi.org\/10.1159\/000452150.","DOI":"10.1159\/000452150"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_007","doi-asserted-by":"crossref","unstructured":"Collett-Solberg, PF, Ambler, G, Backeljauw, PF, Bidlingmaier, M, Biller, BMK, Boguszewski, M, et al.. Diagnosis, genetics, and therapy\u00a0of\u00a0short stature in children: a growth hormone research society\u00a0international perspective. Hormone Res Paediatr 2019;92:1\u201314. https:\/\/doi.org\/10.1159\/000502231.","DOI":"10.1159\/000502231"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_008","doi-asserted-by":"crossref","unstructured":"Oh, JS, Sohn, B, Choi, Y, Song, K, Suh, J, Kwon, A, et al.. The influence of pituitary volume on the growth response in growth hormone-treated children with growth hormone deficiency or idiopathic short stature. Ann Pediatr Endocrinol Metab 2024;29:95\u2013101. https:\/\/doi.org\/10.6065\/apem.2346052.026.","DOI":"10.6065\/apem.2346052.026"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_009","doi-asserted-by":"crossref","unstructured":"Burns, EC, Tanner, JM, Preece, MA, Cameron, N. Final height and pubertal development in 55 children with idiopathic growth hormone deficiency, treated for between 2 and 15 years with human growth hormone. Eur J Pediatr 1981;137:155\u201364. https:\/\/doi.org\/10.1007\/bf00441309.","DOI":"10.1007\/BF00441309"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_010","doi-asserted-by":"crossref","unstructured":"Kastrup, KW, Christiansen, JS, Andersen, JK, Orskov, H. Increased growth rate following transfer to daily SC administration from three weekly IM injections of HGH in growth hormone deficient children. Acta Endocrinol 1983;104:148\u201352. https:\/\/doi.org\/10.1530\/acta.0.1040148.","DOI":"10.1530\/acta.0.1040148"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_011","doi-asserted-by":"crossref","unstructured":"Holdaway, IM, Hunt, P, Manning, P, Cutfield, W, Gamble, G, Ninow, N, et al.. Three-year experience with access to nationally funded growth hormone (GH) replacement for GH-deficient adults. Clin Endocrinol 2015;83:85\u201390. https:\/\/doi.org\/10.1111\/cen.12691.","DOI":"10.1111\/cen.12691"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_012","doi-asserted-by":"crossref","unstructured":"Kremidas, D, Wisniewski, T, Divino, VM, Bala, K, Olsen, M, Germak, J, et al.. Administration burden associated with recombinant human growth hormone treatment: perspectives of patients and caregivers. J Pediatr Nurs 2013;28:55\u201363. https:\/\/doi.org\/10.1016\/j.pedn.2011.12.006.","DOI":"10.1016\/j.pedn.2011.12.006"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_013","doi-asserted-by":"crossref","unstructured":"Pampanini, V, Deodati, A, Inzaghi, E, Cianfarani, S. Long-acting growth hormone preparations and their use in children with growth hormone deficiency. Horm Res Paediatr 2023;96:553\u20139. https:\/\/doi.org\/10.1159\/000523791.","DOI":"10.1159\/000523791"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_014","doi-asserted-by":"crossref","unstructured":"Yuen, KCJ, Miller, BS, Boguszewski, CL, Hoffman, AR. Usefulness and potential pitfalls of long-acting growth hormone analogs. Front Endocrinol 2021;12:637209. https:\/\/doi.org\/10.3389\/fendo.2021.637209.","DOI":"10.3389\/fendo.2021.637209"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_015","doi-asserted-by":"crossref","unstructured":"Hwang, JS, Lee, HS, Chung, WY, Han, HS, Jin, DK, Kim, HS, et al.. Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency. Eur J Endocrinol 2013;169:179\u201385. https:\/\/doi.org\/10.1530\/eje-13-0148.","DOI":"10.1530\/EJE-13-0148"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_016","doi-asserted-by":"crossref","unstructured":"P\u00e9ter, F, Bidlingmaier, M, Savoy, C, Ji, HJ, Saenger, PH. Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). J Clin Endocrinol Metab 2012;97:400\u20137. https:\/\/doi.org\/10.1210\/jc.2011-2234.","DOI":"10.1210\/jc.2011-2234"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_017","doi-asserted-by":"crossref","unstructured":"Khadilkar, V, Radjuk, KA, Bolshova, E, Khadgawat, R, El Kholy, M, Desai, M, et al.. 24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency. J Clin Endocrinol Metab 2014;99:126\u201332. https:\/\/doi.org\/10.1210\/jc.2013-2502.","DOI":"10.1210\/jc.2013-2502"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_018","doi-asserted-by":"crossref","unstructured":"Hou, L, Huang, K, Gong, C, Luo, F, Wei, H, Liang, L, et al.. Long-term pegylated growth hormone for children with growth hormone deficiency: a large, prospective, real-world study. J Clin Endocrinol Metab 2023;108:2078\u201386. https:\/\/doi.org\/10.1210\/clinem\/dgad039.","DOI":"10.1210\/clinem\/dgad039"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_019","doi-asserted-by":"crossref","unstructured":"Chung, S, Yoo, JH, Choi, JH, Rhie, YJ, Chae, HW, Kim, JH, et al.. Design of the long-term observational cohort study with recombinant human growth hormone in Korean children: LG Growth Study. Ann Pediatr Endocrinol Metab 2018;23:43\u201350. https:\/\/doi.org\/10.6065\/apem.2018.23.1.43.","DOI":"10.6065\/apem.2018.23.1.43"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_020","doi-asserted-by":"crossref","unstructured":"Kim, JH, Yun, S, Hwang, SS, Shim, JO, Chae, HW, Lee, YJ, et al.. The 2017 korean national growth charts for children and adolescents: development, improvement, and prospects. Korean J Pediatr 2018;61:135\u201349. https:\/\/doi.org\/10.3345\/kjp.2018.61.5.135.","DOI":"10.3345\/kjp.2018.61.5.135"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_021","doi-asserted-by":"crossref","unstructured":"Bayley, N, Pinneau, SR. Tables\u00a0for predicting adult height from skeletal age: revised for use with the greulich-pyle hand standards. J Pediatr 1952;40:423\u201341. https:\/\/doi.org\/10.1016\/s0022-3476(52)80205-7.","DOI":"10.1016\/S0022-3476(52)80205-7"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_022","doi-asserted-by":"crossref","unstructured":"Hyun, SE, Lee, BC, Suh, BK, Chung, SC, Ko, CW, Kim, HS, et al.. Reference values for serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Korean children and adolescents. Clin Biochem 2012;45:16\u201321. https:\/\/doi.org\/10.1016\/j.clinbiochem.2011.10.003.","DOI":"10.1016\/j.clinbiochem.2011.10.003"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_023","doi-asserted-by":"crossref","unstructured":"Lamb, YN. Lonapegsomatropin: pediatric first approval. Paediatr Drugs 2022;24:83\u201390. https:\/\/doi.org\/10.1007\/s40272-021-00478-8.","DOI":"10.1007\/s40272-021-00478-8"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_024","doi-asserted-by":"crossref","unstructured":"Lamb, YN. Somatrogon: first approval. Drugs 2022;82:227\u201334. https:\/\/doi.org\/10.1007\/s40265-021-01663-2.","DOI":"10.1007\/s40265-021-01663-2"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_025","doi-asserted-by":"crossref","unstructured":"S\u00e4vendahl, L, Battelino, T, H\u00f8jby Rasmussen, M, Brod, M, R\u00f6hrich, S, Saenger, P, et al.. Weekly somapacitan in GH deficiency: 4-year efficacy, safety, and treatment\/disease burden results from REAL 3. J Clin Endocrinol Metab 2023;108:2569\u201378. https:\/\/doi.org\/10.1210\/clinem\/dgad183.","DOI":"10.1210\/clinem\/dgad183"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_026","doi-asserted-by":"crossref","unstructured":"Coutant, R, Bosch Mu\u00f1oz, J, Dumitrescu, CP, Schnabel, D, Sert, C, Perrot, V, et al.. Effectiveness and overall safety of NutropinAq(\u00ae) for growth hormone deficiency and other paediatric growth hormone disorders: completion of the international cooperative growth study, NutropinAq(\u00ae) European registry (iNCGS). Front Endocrinol 2021;12:676083. https:\/\/doi.org\/10.3389\/fendo.2021.676083.","DOI":"10.3389\/fendo.2021.676083"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_027","doi-asserted-by":"crossref","unstructured":"Mameli, C, Orso, M, Calcaterra, V, Wasniewska, MG, Aversa, T, Granato, S, et al.. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: a systematic review and meta-analysis. Pharmacol Res 2023;193:106805. https:\/\/doi.org\/10.1016\/j.phrs.2023.106805.","DOI":"10.1016\/j.phrs.2023.106805"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_028","doi-asserted-by":"crossref","unstructured":"Maniatis, AK, Carakushansky, M, Galcheva, S, Prakasam, G, Fox, LA, Dankovcikova, A, et al.. Treatment burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized study. J Endocr Soc 2022;6:bvac117. https:\/\/doi.org\/10.1210\/jendso\/bvac117.","DOI":"10.1210\/jendso\/bvac117"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_029","doi-asserted-by":"crossref","unstructured":"H\u00f6ybye, C, Christiansen, JS. Long-acting growth hormone. Paediatr Drugs 2013;15:427\u20139. https:\/\/doi.org\/10.1007\/s40272-013-0059-8.","DOI":"10.1007\/s40272-013-0059-8"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_030","doi-asserted-by":"crossref","unstructured":"Christiansen, JS, Backeljauw, PF, Bidlingmaier, M, Biller, BM, Boguszewski, MC, Casanueva, FF, et al.. Research growth hormone society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol 2016;174:C1\u20138. https:\/\/doi.org\/10.1530\/eje-16-0111.","DOI":"10.1530\/EJE-16-0111"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_031","doi-asserted-by":"crossref","unstructured":"Laursen, T, Gravholt, CH, Heickendorff, L, Drustrup, J, Kappelgaard, AM, J\u00f8rgensen, JOL, et al.. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. J Clin Endocrinol Metab 2001;86:1222\u20138. https:\/\/doi.org\/10.1210\/jcem.86.3.7323.","DOI":"10.1210\/jc.86.3.1222"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_032","doi-asserted-by":"crossref","unstructured":"Blum, WF, Alherbish, A, Alsagheir, A, El Awwa, A, Kaplan, W, Koledova, E, et al.. The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. Endocr Connect 2018;7:R212\u2013r22. https:\/\/doi.org\/10.1530\/ec-18-0099.","DOI":"10.1530\/EC-18-0099"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_033","doi-asserted-by":"crossref","unstructured":"Juul, KR, H\u00f8jby Rasmussen, M, Agers\u00f8, H, Overgaard, RV. Optimal monitoring of weekly IGF-I levels during growth hormone therapy with once-weekly somapacitan. J Clin Endocrinol Metab 2021;106:567\u201376. https:\/\/doi.org\/10.1210\/clinem\/dgaa775.","DOI":"10.1210\/clinem\/dgaa775"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_034","doi-asserted-by":"crossref","unstructured":"Lin, Z, Shu, AD, Bach, M, Miller, BS, Rogol, AD. Average IGF-1 prediction for once-weekly lonapegsomatropin in children with growth hormone deficiency. J Endocr Soc 2022;6:bvab168. https:\/\/doi.org\/10.1210\/jendso\/bvab168.","DOI":"10.1210\/jendso\/bvab168"},{"key":"2024120211230932585_j_jpem-2024-0351_ref_035","doi-asserted-by":"crossref","unstructured":"Peter, F, Savoy, C, Ji, HJ, Juhasz, M, Bidlingmaier, M, Saenger, P. Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency. Eur J Endocrinol 2009;160:349\u201355. https:\/\/doi.org\/10.1530\/eje-08-0703.","DOI":"10.1530\/EJE-08-0703"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0351\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0351\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T11:26:34Z","timestamp":1733138794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0351\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,11,18]]},"published-print":{"date-parts":[[2024,12,17]]}},"alternative-id":["10.1515\/jpem-2024-0351"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2024-0351","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}